Article Text

Download PDFPDF

185 Glycoproteomics Reveals Decorin Peptides with Anti-Myostatin Activity In Human Atrial Fibrillation
  1. Javier Barallobre Barreiro1,
  2. Shashi Gupta2,
  3. Anna Zoccarato1,
  4. Rika Kitazume-Taneike1,
  5. Marika Fava1,
  6. Xiaoke Yin1,
  7. Anna Zampetaki1,
  8. Alessandro Viviano3,
  9. Mei Chong1,
  10. Marshall Bern4,
  11. Antonios Kourliouros3,
  12. Nieves Domenech5,
  13. Peter Willeit1,
  14. Ajay M Shah1,
  15. Marjan Jahangiri3,
  16. Liliana Schaefer6,
  17. Jens W Fischer7,
  18. Renato V Iozzo8,
  19. Rosa Viner9,
  20. Thomas Thum2,
  21. Joerg Heineke10,
  22. Antoine Kichler11,
  23. Kinya Otsu1,
  24. Manuel Mayr1
  1. 1King’s College London
  2. 2Institute for Molecular and Translational Therapeutic Strategies, MH-Hannover
  3. 3St Georges Hospital, NHS Trust
  4. 4Protein Metrics
  5. 5Biobanco a Corua, INIBIC-Complexo Hospitalario Universitario de A Corua
  6. 6Klinikum Der Goethe-UniversitäT
  7. 7Institute for Pharmacology and Clinical Pharmacology, Heinrich-Heine-University
  8. 8Sidney Kimmel Medical College at Thomas Jefferson University
  9. 9Thermo Fisher Scientific
  10. 10Experimental Cardiology, Department of Cardiology and Angiology, MH-Hannover
  11. 11Laboratoire Vecteurs: SynthèSe Et Applications ThéRapeutiques, UMR 7199 CNRS Université de Strasbourg


Background Myocardial fibrosis is a feature of many cardiac diseases. We used proteomics to profile glycoproteins in the human cardiac extracellular matrix (ECM).

Methods and Results Atrial specimens were analysed by mass spectrometry after extraction of ECM proteins and enrichment for glycoproteins or glycopeptides. Out of all ECM proteins identified, the small leucine-rich proteoglycan decorin was found to be the most fragmented. Within its protein core, eighteen different cleavage sites were identified. In contrast, no cleavage was observed for biglycan, the most closely related proteoglycan. Decorin processing differed between human ventricles and atria and was altered in disease. The C-terminus of decorin, important for the interaction with connective tissue growth factor, was predominantly detected in ventricles compared to atria. In contrast, atrial appendages from patients in persistent atrial fibrillation had higher levels of full-length decorin but also harboured a cleavage site that was not found in atrial appendages from patients in sinus rhythm. This cleavage site preceded the N-terminal domain of decorin that controls muscle growth by altering the binding capacity for myostatin. Myostatin expression was decreased in atrial appendages of patients with persistent persistent atrial fibrillation and hearts of decorin null mice. A synthetic peptide corresponding to this decorin region dose-dependently inhibited the response to myostatin in cardiac myocytes and in perfused mouse hearts.

Conclusion This proteomics study is the first to analyse the human cardiac ECM. Novel processed forms of decorin protein core, uncovered in human atrial appendages can regulate the local bioavailability of anti-hypertrophic and pro-fibrotic growth factors.

  • Extracellular matrix
  • atrial fibrillation
  • proteomics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.